Clicky

Imugene Limited  (IMU)

Description: Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and oncology targets.


Keywords: Medicine Pharmaceutical Cancer Biopharmaceutical Gas Antibodies Oncology Tumor Immunotherapy Breast Cancer Clinical Trial Cancer Immunotherapy Immunotherapies Her2/Neu Metastatic Breast Cancer Health Technologies Imugene

Home Page: www.imugene.com

IMU Technical Analysis

Transamerica Funds
,

Phone: 888-233-4339


Officers

Name Title
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Exec. Chairman
Ms. Leslie Chong CEO, MD & Exec. Director
Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D. Chief Technology Officer
Dr. Monil Shah M.B.A., Pharm.D. Chief Bus. Officer
Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD Chief Financial Officer
Ms. Ursula McCurry Sr. VP of Clinical Operations
Dr. Giovanni Selvaggi Chief Medical Officer
Mr. Nathan Jong C.A. Joint Company Sec.

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 8.5651
Price-to-Sales TTM: 81.6957
IPO Date:
Fiscal Year End: June
Full Time Employees: 0
Back to stocks